Analyst Ratings For Nektar Therapeutics (NASDAQ:NKTR)
Today, Jefferies Group raised its price target on Nektar Therapeutics (NASDAQ:NKTR) to per share.
Some recent analyst ratings include
- 2/14/2018-Mizuho Reiterated Rating of Buy.
- 11/13/2017-JPMorgan Chase & Co. Reiterated Rating of Positive .
- 11/7/2017-Cowen initiated coverage with a Outperform rating.
Recent Insider Trading Activity For Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics (NASDAQ:NKTR) has insider ownership of 6.10% and institutional ownership of 96.23%.
- On 2/16/2018 Gil M. Labrucherie, CFO, sold 3,477 with an average share price of $82.94 per share and the total transaction amounting to $288,382.38.
- On 2/16/2018 Howard W Robin, CEO, sold 12,788 with an average share price of $82.94 per share and the total transaction amounting to $1,060,636.72.
- On 2/16/2018 Jillian B. Thomsen, CAO, sold 2,545 with an average share price of $82.94 per share and the total transaction amounting to $211,082.30.
- On 2/16/2018 John Nicholson, COO, sold 4,879 with an average share price of $82.94 per share and the total transaction amounting to $404,664.26.
- On 2/16/2018 Stephen K Doberstein, SVP, sold 2,426 with an average share price of $82.94 per share and the total transaction amounting to $201,212.44.
- On 1/22/2018 Howard W Robin, CEO, sold 83,333 with an average share price of $75.82 per share and the total transaction amounting to $6,318,308.06.
- On 1/2/2018 Christopher A Kuebler, Director, sold 30,000 with an average share price of $58.66 per share and the total transaction amounting to $1,759,800.00.
Recent Trading Activity for Nektar Therapeutics (NASDAQ:NKTR)
Shares of Nektar Therapeutics closed the previous trading session at 96.66 up +12.10 14.32% with 88.5 shares trading hands.